Nymox Pharmaceutical annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical Stock-Based Compensation Growth & History (NYMXF)
Nymox Pharmaceutical's stock-based compensation was $671,000 for fiscal 2024.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $671,000 | −$2.7M | −80.01% |
| 2023 | 2023-12-31 | $3.4M | $2.8M | +466.10% |
| 2022 | 2022-12-31 | $593,000 | −$2.0M | −77.22% |
| 2021 | 2021-12-31 | $2.6M | $855,000 | +48.91% |
| 2020 | 2020-12-31 | $1.7M | −$1.3M | −41.95% |
| 2019 | 2019-12-31 | $3.0M | −$803,000 | −21.05% |
| 2018 | 2018-12-31 | $3.8M | −$2.5M | −39.43% |
| 2017 | 2017-12-31 | $6.3M | −$2.8M | −30.60% |
| 2016 | 2016-12-31 | $9.1M | −$6.7M | −42.51% |
| 2015 | 2015-12-31 | $15.8M | — | — |
Nymox Pharmaceutical quarterly stock-based compensation
Q1.17
Q2.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $159,000 | −$3.1M | −95.10% |
| Q4 2023 | 2023-12-31 | $3.2M | $3.2M | +3761.90% |
| Q3 2023 | 2023-09-30 | $11,000 | −$22,000 | −66.67% |
| Q2 2023 | 2023-06-30 | $32,000 | −$350,000 | −91.62% |
| Q1 2023 | 2023-03-31 | $70,000 | −$24,000 | −25.53% |
| Q4 2022 | 2022-12-31 | $84,000 | −$637,000 | −88.35% |
| Q3 2022 | 2022-09-30 | $33,000 | −$141,000 | −81.03% |
| Q2 2022 | 2022-06-30 | $382,000 | −$1.0M | −73.21% |
| Q1 2022 | 2022-03-31 | $94,000 | −$188,000 | −66.67% |
| Q4 2021 | 2021-12-31 | $721,000 | $392,000 | +119.15% |
| Q3 2021 | 2021-09-30 | $174,000 | −$202,000 | −53.72% |
| Q2 2021 | 2021-06-30 | $1.4M | $991,000 | +227.82% |
| Q1 2021 | 2021-03-31 | $282,000 | −$326,000 | −53.62% |
| Q4 2020 | 2020-12-31 | $329,000 | −$156,000 | −32.16% |
| Q3 2020 | 2020-09-30 | $376,000 | −$170,000 | −31.14% |
| Q2 2020 | 2020-06-30 | $435,000 | −$855,000 | −66.28% |
| Q1 2020 | 2020-03-31 | $608,000 | −$82,000 | −11.88% |
| Q4 2019 | 2019-12-31 | $485,000 | −$265,000 | −35.33% |
| Q3 2019 | 2019-09-30 | $546,000 | −$597,000 | −52.23% |
| Q2 2019 | 2019-06-30 | $1.3M | $376,000 | +41.14% |
| Q1 2019 | 2019-03-31 | $690,000 | −$317,000 | −31.48% |
| Q4 2018 | 2018-12-31 | $750,000 | — | — |
| Q3 2018 | 2018-09-30 | $1.1M | — | — |
| Q2 2018 | 2018-06-30 | $914,000 | −$437,000 | −32.35% |
| Q1 2018 | 2018-03-31 | $1.0M | −$525,000 | −34.27% |
| Q2 2017 | 2017-06-30 | $1.4M | — | — |
| Q1 2017 | 2017-03-31 | $1.5M | — | — |
Nymox Pharmaceutical stock-based compensation trends
Over the last five fiscal years, Nymox Pharmaceutical's stock-based compensation decreased from $3.0M to $671,000, a change of −$2.3M. The latest reported quarter, Q4 2024, shows $159,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nymox Pharmaceutical source filings ↗